Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
暂无分享,去创建一个
Sharon-Lise Normand | Adrian Towse | Art Sedrakyan | Nancy Dreyer | Marc L Berger | N. Dreyer | S. Normand | A. Towse | M. Berger | A. Sedrakyan | Fred Anderson | Fred Anderson
[1] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[2] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[3] D. Rubin. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials , 2007, Statistics in medicine.
[4] R. Lilford. Response from chair of scientific advisory committee , 2010, BMJ : British Medical Journal.
[5] J. Gardin,et al. Low cardiovascular risk is associated with favorable left ventricular mass, left ventricular relative wall thickness, and left atrial size: the CARDIA study. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[6] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] D. Price,et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. , 2011, The New England journal of medicine.
[8] S. Goodman,et al. Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.
[9] E. Vicaut,et al. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.
[10] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[11] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[12] new drug application (NDA) , 2009 .
[13] Ian Harvey,et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers , 2009, Canadian Medical Association Journal.
[14] T. Greene,et al. A Simulation-Based Evaluation of Methods to Estimate the Impact of an Adverse Event on Hospital Length of Stay , 2007, Medical care.
[15] Jeffrey M. Woodbridge. Econometric Analysis of Cross Section and Panel Data , 2002 .
[16] M. Buyse,et al. Cancer Clinical Trials: Methods and Practice. , 1985 .
[17] M. Epstein,et al. Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .
[18] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[19] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[20] Noel S Weiss,et al. The New World of Data Linkages in Clinical Epidemiology: Are We Being Brave or Foolhardy? , 2011, Epidemiology.
[21] N. Dreyer,et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. , 2010, The Journal of infectious diseases.
[22] Frederic S. Resnic,et al. Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.
[23] F. Van de Werf,et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) , 2005, Heart.
[24] D P Hartmann,et al. Interrupted time-series analysis and its application to behavioral data. , 1980, Journal of applied behavior analysis.
[25] H. Kraemer,et al. Caution regarding the use of pilot studies to guide power calculations for study proposals. , 2006, Archives of general psychiatry.
[26] A. LaCroix,et al. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design , 2009, Osteoporosis International.
[27] J. Avorn,et al. Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information , 2007, Medical care.
[28] W. Shadish,et al. Experimental and Quasi-Experimental Designs for Generalized Causal Inference , 2001 .
[29] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[30] J. Broadhead,et al. WHO consensus statement. , 1990, The British journal of psychiatry : the journal of mental science.
[31] N. Dreyer,et al. Good Practices for Handling Adverse Events Detected through Patient Registries , 2008 .
[32] Vanessa Didelez,et al. Assumptions of IV methods for observational epidemiology , 2010, 1011.0595.
[33] Uwe Siebert,et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retr , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] S. Normand,et al. Improving traditional intention-to-treat analyses: a new approach , 2005, Psychological Medicine.
[35] Richard E Gliklich,et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. , 2010, The American journal of managed care.
[36] Clarence Balden Randall,et al. Report to the President and the Congress , 1954 .
[37] D. Moher,et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.
[38] Tom Gross,et al. A framework for evidence evaluation and methodological issues in implantable device studies. , 2010, Medical care.
[39] Marianne Klemp,et al. What principles should govern the use of managed entry agreements? , 2011, International Journal of Technology Assessment in Health Care.
[40] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.
[41] M. Epstein. Guidelines for good pharmacoepidemiology practices (GPP) , 2005, Pharmacoepidemiology and drug safety.
[42] Amela,et al. CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER , 2000 .
[43] James M. Robins,et al. Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.
[44] Luciano Picarelli,et al. Final Report 2008 , 2008 .
[45] David Atkins,et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[46] J. Lewsey,et al. Variation in use of video assisted thoracic surgery in the United Kingdom , 2004, BMJ : British Medical Journal.
[47] Using Multiple Control Groups and Matching to Address Unobserved Biases in Comparative Effectiveness Research , 2011, Statistics in biosciences.
[48] J. Avorn,et al. Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results , 2007, Medical care.
[49] Ellen Frank,et al. Moderators of treatment outcomes: clinical, research, and policy importance. , 2006, JAMA.
[50] T. Brennan,et al. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. , 2001, Health affairs.
[51] R. Weintraub,et al. Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia , 2012, PharmacoEconomics.
[52] K. Alexander,et al. Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. , 2010, American heart journal.
[53] S. Williamson. Patient access schemes for high-cost cancer medicines. , 2010, The Lancet. Oncology.
[54] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.
[55] J. Coyne,et al. Research to improve the quality of care for depression: alternatives to the simple randomized clinical trial. , 2003, General hospital psychiatry.
[56] U. Dafni. Landmark Analysis at the 25-Year Landmark Point , 2011, Circulation. Cardiovascular quality and outcomes.
[57] Richard L Kravitz,et al. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.
[58] M. Graffar. [Modern epidemiology]. , 1971, Bruxelles medical.
[59] J. D. Miller. Sharing clinical research data in the United States under the health insurance portability and accountability act and the privacy rule , 2010, Trials.
[60] S. Martino,et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.
[61] Michael L. Johnson,et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[62] Sander Greenland,et al. Modern Epidemiology 3rd edition , 1986 .
[63] Dylan S. Small,et al. Sensitivity Analysis for Instrumental Variables Regression With Overidentifying Restrictions , 2007 .
[64] B. Freedman. Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.
[65] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.